BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg. 2012;255:319-325. [PMID: 22241292 DOI: 10.1097/SLA.0b013e31823e3a1c] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Yu X, Zheng Y, Zhu X, Gao X, Wang C, Sheng Y, Cheng W, Qin L, Ren N, Jia H, Dong Q. Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. Oncol Lett 2018;16:5299-308. [PMID: 30250599 DOI: 10.3892/ol.2018.9281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
2 Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MA, Franzen CA, Gupta GN, Osipo C, Zlobin A, Syn WK, Zhang J, Kuo PC, Mi Z. Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 2015;34:4821-33. [PMID: 25531323 DOI: 10.1038/onc.2014.410] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 12.3] [Reference Citation Analysis]
3 Nambotin SB, Tomimaru Y, Merle P, Wands JR, Kim M. Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis 2012;1:e31. [PMID: 23552403 DOI: 10.1038/oncsis.2012.31] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
4 Sun B, Zhang Z. [Advances in Research of Osteopontion and Its Receptor CD44v in Tumor Invasion and Metastasis]. Zhongguo Fei Ai Za Zhi 2015;18:714-7. [PMID: 26582229 DOI: 10.3779/j.issn.1009-3419.2015.11.11] [Reference Citation Analysis]
5 Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, Sheng Y, Zheng Y, Yu J, Xie L, Qin Y, Qiao P, Zhou C, Yu X, Jia H, Ren N, Zhou H, Ye Q, Qin L. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget 2016;7:12997-3012. [PMID: 26824421 DOI: 10.18632/oncotarget.7016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
6 Liu CW, Li CH, Peng YJ, Cheng YW, Chen HW, Liao PL, Kang JJ, Yeng MH. Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer. Oncotarget 2014;5:3880-94. [PMID: 25003810 DOI: 10.18632/oncotarget.2006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
7 Parashar A. Aptamers in Therapeutics. J Clin Diagn Res 2016;10:BE01-6. [PMID: 27504277 DOI: 10.7860/JCDR/2016/18712.7922] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
8 Ladju RB, Pascut D, Massi MN, Tiribelli C, Sukowati CHC. Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma. Oncotarget 2018;9:2951-61. [PMID: 29416827 DOI: 10.18632/oncotarget.23359] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
9 Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (Basel) 2020;12:E3379. [PMID: 33203146 DOI: 10.3390/cancers12113379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
10 Kothari AN, Arffa ML, Chang V, Blackwell RH, Syn WK, Zhang J, Mi Z, Kuo PC. Osteopontin-A Master Regulator of Epithelial-Mesenchymal Transition. J Clin Med 2016;5:E39. [PMID: 27023622 DOI: 10.3390/jcm5040039] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
11 Xu H, Wang H, Zhao W, Fu S, Li Y, Ni W, Xin Y, Li W, Yang C, Bai Y, Zhan M, Lu L. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma. Theranostics 2020;10:5671-86. [PMID: 32483411 DOI: 10.7150/thno.42539] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
12 Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci 2016;12:1121-8. [PMID: 27570486 DOI: 10.7150/ijbs.16445] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
13 Zapf MA, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, Gupta GN, Kuo PC, Mi Z. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma. Surgery 2015;158:1039-47; discussion 1047-8. [PMID: 26189955 DOI: 10.1016/j.surg.2015.06.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
14 Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, Orringer MB, Reddy RM, Chang AC, Beer DG, Lin L. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 2015;6:22239-57. [PMID: 26068949 DOI: 10.18632/oncotarget.4161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
15 Sun JY, Xu JM, Yan M, Ye F. Advances in understanding relationship between osteopontin and metastasis and recurrence of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1498-1504 [DOI: 10.11569/wcjd.v21.i16.1498] [Reference Citation Analysis]